FDA

Explore The Latest FDA News And Updates On Drug Approvals And More

Brain Cancer

FDA Grants FTD tp Telixs...

FDA has granted Fast Track designation (FTD) to Telix Pharmaceuticals…

Other Cancers

FDA Approves Illumina’s Test for...

FDA has approved Illumina’s TruSight Oncology Comprehensive (TSO Comprehensive) test,…

Lung Cancer

FDA Grants BTD to Boehringer’s...

FDA has granted Breakthrough Therapy Designation (BTD) to Boehringer Ingelheim…

FDA Grants ODD to RedHill’s Opaganib for Pediatric Neuroblastoma

FDA Issues CRL to Regeneron for Linvoseltamab BLA in RRMM

FDA Accepts Bristol’s sBLA for Opdivo®+Yervoy® as 1L Treatment for HCC

SELECT ONCOLOGY JOURNAL ARTICLES

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …

BMJ Journals

Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

BMJ Journals

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …

BMJ Journals

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is …

BMJ Journals

FDA

FDA Grants FTD tp Telixs...

FDA Approves Illumina’s Test for...

FDA Grants BTD to Boehringer’s...

FDA Grants ODD to RedHill’s Opaganib for Pediatric Neuroblastoma

FDA Issues CRL to Regeneron for Linvoseltamab BLA in RRMM

FDA Accepts Bristol’s sBLA for Opdivo®+Yervoy® as 1L Treatment for HCC

Explore More

FDA Approves Janssen’s Lazertinib+Amivantamab-Vmjw for NSCLC

FDA Grants ODD to Phanes Therapeutics’ PT217 for NEC Treatment

SELECT ONCOLOGY JOURNAL ARTICLES

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial

Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma

1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)

Clinical Trial Portal

FDA

FDA Grants ODD to Abdera’...

Sign up for our emails

Newsletter

Explore More

SELECT ONCOLOGY JOURNAL ARTICLES

Footer Newsletter